KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Common Equity (2016 - 2025)

Historic Common Equity for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to -$2.6 billion.

  • AbbVie's Common Equity fell 14351.84% to -$2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 billion, marking a year-over-year decrease of 14351.84%. This contributed to the annual value of $3.4 billion for FY2024, which is 6764.45% down from last year.
  • Per AbbVie's latest filing, its Common Equity stood at -$2.6 billion for Q3 2025, which was down 14351.84% from -$138.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's Common Equity registered a high of $17.3 billion during Q4 2022, and its lowest value of -$2.6 billion during Q3 2025.
  • Over the past 5 years, AbbVie's median Common Equity value was $12.6 billion (recorded in 2021), while the average stood at $10.1 billion.
  • Per our database at Business Quant, AbbVie's Common Equity surged by 28520.57% in 2021 and then tumbled by 14351.84% in 2025.
  • AbbVie's Common Equity (Quarter) stood at $15.4 billion in 2021, then rose by 11.99% to $17.3 billion in 2022, then plummeted by 39.86% to $10.4 billion in 2023, then tumbled by 67.64% to $3.4 billion in 2024, then tumbled by 178.54% to -$2.6 billion in 2025.
  • Its Common Equity was -$2.6 billion in Q3 2025, compared to -$138.0 million in Q2 2025 and $1.5 billion in Q1 2025.